JP7160466B2 - 治療薬の送達のための組成物及び方法 - Google Patents

治療薬の送達のための組成物及び方法 Download PDF

Info

Publication number
JP7160466B2
JP7160466B2 JP2018567638A JP2018567638A JP7160466B2 JP 7160466 B2 JP7160466 B2 JP 7160466B2 JP 2018567638 A JP2018567638 A JP 2018567638A JP 2018567638 A JP2018567638 A JP 2018567638A JP 7160466 B2 JP7160466 B2 JP 7160466B2
Authority
JP
Japan
Prior art keywords
acid
nanoparticles
prodrug
hiv
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018567638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524670A (ja
JP2019524670A5 (OSRAM
Inventor
エダグワ，ベンソン，ジェイ．
ジェンデルマン，ホワード，イー．
ジョーンズ，ブライアン，アルビン
Original Assignee
ヴィーブ ヘルスケア カンパニー
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィーブ ヘルスケア カンパニー, ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ filed Critical ヴィーブ ヘルスケア カンパニー
Publication of JP2019524670A publication Critical patent/JP2019524670A/ja
Publication of JP2019524670A5 publication Critical patent/JP2019524670A5/ja
Application granted granted Critical
Publication of JP7160466B2 publication Critical patent/JP7160466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2018567638A 2016-06-23 2017-06-22 治療薬の送達のための組成物及び方法 Active JP7160466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353736P 2016-06-23 2016-06-23
US62/353,736 2016-06-23
PCT/US2017/038693 WO2017223280A2 (en) 2016-06-23 2017-06-22 Compositions and methods for the delivery of therapeutics

Publications (3)

Publication Number Publication Date
JP2019524670A JP2019524670A (ja) 2019-09-05
JP2019524670A5 JP2019524670A5 (OSRAM) 2020-05-07
JP7160466B2 true JP7160466B2 (ja) 2022-10-25

Family

ID=60784694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567638A Active JP7160466B2 (ja) 2016-06-23 2017-06-22 治療薬の送達のための組成物及び方法

Country Status (5)

Country Link
US (1) US11117904B2 (OSRAM)
EP (3) EP4299133A3 (OSRAM)
JP (1) JP7160466B2 (OSRAM)
ES (1) ES3035041T3 (OSRAM)
WO (1) WO2017223280A2 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US20200407393A1 (en) * 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
EP4234560A3 (en) * 2018-10-22 2023-09-13 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN113382737B (zh) 2018-11-29 2025-06-03 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
US20220096503A1 (en) * 2019-01-11 2022-03-31 University Of Washington Combination pharmaceutical compositions and methods thereof
EP3934760A1 (en) 2019-03-06 2022-01-12 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
IL286328B1 (en) 2019-03-22 2026-04-01 Gilead Sciences Inc Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use
CA3164528A1 (en) * 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
JP7591155B2 (ja) 2021-01-19 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド 置換ピリドトリアジン化合物及びその使用
WO2023183472A1 (en) * 2022-03-23 2023-09-28 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and use thereof
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4619400A4 (en) * 2023-01-18 2026-03-25 Ascletis Bioscience Co Ltd Integrase inhibitor and its use
KR20260022300A (ko) * 2023-04-26 2026-02-19 유니버시티 오브 워싱톤 인테그레이즈 가닥 전이 억제제의 장기 작용형 콜로이드형 약제학적 조성물 및 관련 방법
WO2025011661A1 (zh) * 2023-07-12 2025-01-16 歌礼生物科技（杭州）有限公司 整合酶抑制类的制剂及其制备方法
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2026012272A1 (en) * 2024-07-12 2026-01-15 Ascletis Bioscience Co., Ltd. Integrase inhibitor and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018065A1 (ja) 2010-08-05 2012-02-09 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する化合物の製造方法
JP2014500849A (ja) 2010-09-16 2014-01-16 ヴィーブ ヘルスケア カンパニー 医薬組成物
JP2014141486A (ja) 2012-12-27 2014-08-07 Japan Tobacco Inc 置換されたスピロピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015127437A1 (en) 2014-02-24 2015-08-27 The Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1874117E (pt) 2005-04-28 2013-10-17 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse
CN103951643B (zh) * 2008-07-25 2015-12-09 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SI2320908T1 (sl) * 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
JP2013542945A (ja) 2010-11-02 2013-11-28 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 治療を送達するための組成物および方法
CA2893843C (en) * 2012-12-21 2018-09-04 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018065A1 (ja) 2010-08-05 2012-02-09 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する化合物の製造方法
JP2014500849A (ja) 2010-09-16 2014-01-16 ヴィーブ ヘルスケア カンパニー 医薬組成物
JP2014141486A (ja) 2012-12-27 2014-08-07 Japan Tobacco Inc 置換されたスピロピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015127437A1 (en) 2014-02-24 2015-08-27 The Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZARO,Jennica L.，The AAPS Journal，2015年，17(1)，83-92

Also Published As

Publication number Publication date
WO2017223280A3 (en) 2019-04-25
US20210230186A1 (en) 2021-07-29
US11117904B2 (en) 2021-09-14
EP4299133A3 (en) 2024-03-13
EP3474857A2 (en) 2019-05-01
ES3035041T3 (en) 2025-08-27
EP3474857A4 (en) 2020-03-18
EP3474857C0 (en) 2025-05-21
EP4527463A3 (en) 2025-06-25
EP4299133A2 (en) 2024-01-03
EP4527463A2 (en) 2025-03-26
JP2019524670A (ja) 2019-09-05
EP3474857B1 (en) 2025-05-21
WO2017223280A2 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
US11117904B2 (en) Compositions and methods for the delivery of therapeutics
US20220211714A1 (en) Compositions and methods for the delivery of therapeutics
JP7437051B2 (ja) 抗ウイルスプロドラッグおよびそのナノ製剤
US12257306B2 (en) Antiviral prodrugs and nanoformulations thereof
US20170165271A1 (en) Compositions and Methods for the Delivery of Therapeutics
US11839623B2 (en) Antiviral prodrugs and formulations thereof
CN114599365A (zh) 前药及其制剂
US20160136105A1 (en) Compositions and Methods for the Delivery of Therapeutics
US11458136B2 (en) Antiviral prodrugs and formulations thereof
US20180028457A1 (en) Compositions and Methods for the Delivery of Therapeutics

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221007

R150 Certificate of patent or registration of utility model

Ref document number: 7160466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150